Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 6/20 | 0.45 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.45 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.45 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | WNT3 | P56703 | 1/20 | 0.40 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fasoracetam SCHEMBL23922653 | 1.00 | HPGD (0.47) | HPGDNAMPTTPSAB1TPSD1TPSG1 | |
| SCHEMBL9735864 | 1.00 | HPGD (0.47) | HPGDNAMPTTPSAB1TPSD1TPSG1 | |
| Fasoracetam SCHEMBL194770 | 1.00 | HPGD (0.47) | HPGDNAMPTTPSAB1TPSD1TPSG1 | |
| Fasoracetam SCHEMBL194771 | 1.00 | HPGD (0.47) | HPGDNAMPTTPSAB1TPSD1TPSG1 | |
| Fasoracetam SCHEMBL18323021 | 0.98 | HPGD (0.46) | HPGDNAMPTTPSAB1TPSD1TPSG1 | |
| SCHEMBL9736271 | 0.98 | NAMPT (0.46) | HPGDNAMPTTPSAB1TPSD1TPSG1 | |
| SCHEMBL9734368 | 0.98 | NAMPT (0.46) | HPGDNAMPTTPSAB1TPSD1TPSG1 | |
| SCHEMBL5971671 | 0.98 | NAMPT (0.46) | HPGDNAMPTTPSAB1TPSD1TPSG1 | |
| Fasoracetam SCHEMBL21178002 | 0.95 | NAMPT (0.43) | HPGDNAMPTTPSAB1TPSD1TPSG1 | |
| SCHEMBL7955572 | 0.93 | NAMPT (0.48) | HPGDNAMPTTPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5102882-A | Nootropic agents | NIPPON SHINYAKU CO., LTD. (JP) | 1992-04-07 | — | — | US | claimed |
| JP-63146857-A | — | — | None | — | — | JP | disclosed |
| US-8962676-B2 | Causal therapy of diseases or conditions associated with CNS or PNS demyelination | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-02-24 | — | — | US | disclosed |
| US-8962676-B2 | Causal therapy of diseases or conditions associated with CNS or PNS demyelination | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-02-24 | — | — | US | disclosed |
| US-20120269762-A1 | CAUSAL THERAPY OF DISEASES OR CONDITIONS ASSOCIATED WITH CNS OR PNS DEMYELINATION | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2012-10-25 | — | — | US | disclosed |
| US-20120269762-A1 | CAUSAL THERAPY OF DISEASES OR CONDITIONS ASSOCIATED WITH CNS OR PNS DEMYELINATION | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2012-10-25 | — | — | US | disclosed |
| US-20100048634-A1 | METHOD FOR TREATING APATHY SYNDROME | CHA ALBERT | 2010-02-25 | — | — | US | disclosed |
| US-20100048634-A1 | METHOD FOR TREATING APATHY SYNDROME | CHA ALBERT | 2010-02-25 | — | — | US | disclosed |
| US-5102882-A | Nootropic agents | NIPPON SHINYAKU CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| JP-S63146857-A | PYROGLUTAMIDE DERIVATIVE AND PRODUCTION THEREOF | NIPPON SHINYAKU CO LTD | 1988-06-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269762-A1 | CAUSAL THERAPY OF DISEASES OR CONDITIONS ASSOCIATED WITH CNS OR PNS DEMYELINATION | PMP22, MYT1, SMN1; SMN2 | HPGD 4251/4885NAMPT 1933/4885TPSAB1 4359/4885 |
| US-20100048634-A1 | METHOD FOR TREATING APATHY SYNDROME | PNMT, NEFM, NNMT | HPGD 2521/4885NAMPT 227/4885TPSAB1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.